The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Verrica Pharmaceuticals Inc shares valued at $10,000 were purchased by Rosenberg Noah L. on Nov 25 ’25. At $4.24 per share, Rosenberg Noah L. acquired 2,357 shares. The insider’s holdings grew to 2,357 shares worth approximately $19586.670000000002 following the completion of this transaction.
Also, Kirby John J. purchased 3,536 shares, netting a total of over 15,001 in proceeds. Following the buying of shares at $4.24 each, the insider now holds 8,962 shares.
Before that, Zawitz David had added 10,000 shares to its account. In a trade valued at $42,425, the Chief Operating Officer bought Verrica Pharmaceuticals Inc shares for $4.24 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $0.17 million.
As published in a research note from H.C. Wainwright on November 06, 2024, Verrica Pharmaceuticals Inc [VRCA] has been rated down from a Buy to a Neutral. Analysts at RBC Capital Mkts downgraded the stock from ‘”an Outperform”‘ to ‘”a Sector perform”‘ outlook in a report released in early November. As of July 25, 2023, Needham has increased its “Hold” rating to a “Buy” for VRCA. Earlier on March 22, 2023, Jefferies initiated its rating. Their recommendation was “a Buy” for VRCA stock.
Analyzing VRCA Stock Performance
On last trading session, Verrica Pharmaceuticals Inc [NASDAQ: VRCA] rose 0.12% to $8.31. The stock’s lowest price that day was $8.08, but it reached a high of $8.7 in the same session. During the last five days, there has been a surge of approximately 1.22%. Over the course of the year, Verrica Pharmaceuticals Inc shares have jumped approximately 21.44%. Shares of the company reached a 52-week high of $9.82 on 11/28/25 and a 52-week low of $3.28 on 11/04/25.
Support And Resistance Levels for Verrica Pharmaceuticals Inc (VRCA)
According to the 24-hour chart, there is a support level at 8.03, which, if violated, would cause prices to drop to 7.74. In the upper region, resistance lies at 8.65. The next price resistance is at 8.98. RSI (Relative Strength Index) is 60.23 on the 14-day chart, showing neutral technical sentiment.
Is Verrica Pharmaceuticals Inc subject to short interest?
Stocks of Verrica Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-15 dropping by 66130.0 shares to 0.38 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 0.45 million shares. A decline of -17.38% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.91 of the overall float, the days-to-cover ratio (short ratio) decline to 0.91.
Which companies own the most shares of Verrica Pharmaceuticals Inc (VRCA)?
In terms of Verrica Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 17 in the next 12 months, up nearly 104.82% from the previous closing price of $8.3. Analysts anticipate Verrica Pharmaceuticals Inc stock to reach 17 by 2026, with the lowest price target being 17. In spite of this, 4 analysts ranked Verrica Pharmaceuticals Inc stock as Buy at the end of 2026. On February 13, 2023, RBC Capital Mkts assigned a price target of “an Outperform” to the stock and upgraded coverage with a $11.
